News

Advancis’ pediatric pivotal program is designed as a 500-patient, investigator-blind, non-inferiority phase III trial for a ‘sprinkle’ formulation of amoxicillin Pulsys for the treatment of pediatric patients with

The clinical study was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of pradefovir (formerly called remofovir) in patients chronically infected with hepatitis B virus (HBV). In

Group net sales were up 11% to $7.3 billion, driven by pharmaceuticals, which once again gained market share, and its recently acquired generics division Sandoz, which posted a

Researchers found that the enzyme, hDOT1L, activates a set of genes that play a key role in acute myeloid leukemia (AML), a rare form of leukemia. The new

Further to the 7 April, 2005 statement on the suspension of use of Bextra (valdecoxib), the Committee for Medicinal Products for Human Use (CHMP) of the EMEA held

Under the terms of the agreement, Debiopharm will fund the entire development of the product. In addition, NanoCarrier will receive cash milestones at different stages of the development

The new lease replaces VaxGen’s previous sublease for approximately 50,000 square feet and provides an additional 25,000 square feet of new space for immediate use and another 30,000

Low-dose doxepin demonstrated efficacy in its primary endpoint, wake time during sleep (WTDS) at all doses studied (1mg, 3mg and 6mg). Low-dose doxepin also demonstrated efficacy in all

Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that has been linked to a nonsense mutation in the dystrophin gene. It is estimated that 15% of the